CIP2A protein level in MNCs and CD34⁺ at diagnosis is predictive of BC. (A) mRNA expression of CIP2A. No statistically significant difference was observed between any of the 3 response groups. CCR, n = 9; No-CCR, n = 9; and BC, n = 6. (B) Levels of CIP2A protein (mean level in 10 healthy subjects = 0.4; range, 0.17-0.63). CIP2A protein levels at diagnosis were significantly higher at diagnosis in patients who later progressed to BC than in CCR or No-CCR patients (P < .0001 and P = .01, respectively). As a patient progresses into BC, the CIP2A protein level increases further (P = .008). CCR, n = 11; No-CCR, n = 9; and BC, n = 6. (C) Level of CIP2A protein in diagnostic CD34⁺ cells stratified by the patients' clinical outcome. CIP2A is elevated in CD34 from patients destined to progress into BC. CCR, n = 3; No-CCR, n = 4; and BC, n = 3. (D) Kaplan-Meier plot of disease progression, stratified by CIP2A level at diagnosis. Patients with a high diagnostic CIP2A protein level (mean fluorescence intensity [MFI] > 5) have 100% probability of progressing to BC by 21 months (P < .0001). (E) CIP2A levels (mean ± SEM) in CML cell lines K562, KCL22, KY01, and a CIP2A-positive gastric cancer cell line AGS, before and after treatment with 5μM imatinib for 24 hours (n = 6).